Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis

This perspective presents and supports arguments for a new formulation of epoxy-α-lapachone loaded microemulsion (ELAP-ME), a nanosystem, as a prototype drug for the treatment of leishmaniasis. The benefits of ELAP as a multitarget compound, with properties that affect key physiological pathways of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Memórias do Instituto Oswaldo Cruz 2024, Vol.119, p.e240115
Hauptverfasser:	Peixoto, Juliana Figueiredo, Gonçalves-Oliveira, Luiz Filipe, Dias-Lopes, Geovane, Souza-Silva, Franklin, Alves, Carlos Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiprotozoal Agents - administration & dosage Disease Models, Animal Leishmania mexicana - drug effects Leishmaniasis, Cutaneous - drug therapy Mice Mice, Inbred BALB C Naphthoquinones PARASITOLOGY TROPICAL MEDICINE
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This perspective presents and supports arguments for a new formulation of epoxy-α-lapachone loaded microemulsion (ELAP-ME), a nanosystem, as a prototype drug for the treatment of leishmaniasis. The benefits of ELAP as a multitarget compound, with properties that affect key physiological pathways of Leishmania spp. are discussed. ELAP-ME demonstrated efficacy in murine infection models, particularly with the binomial BALB/c-Leishmania (Leishmania) amazonensis. Furthermore, it is proposed that the technological maturity of ELAP-ME be classified as Technology Readiness Level 4 (TLR 4) within the context of innovative drugs for American Cutaneous Leishmaniasis (ACL).
ISSN:	0074-0276 1678-8060 1678-8060
DOI:	10.1590/0074-02760240115